However, our results indicated that FDX1 did not exhibit a difference between NAFLD and control liver samples, unlike Tsvetkov’s findings that FDX1 is a key regulator in cuproptosis. Here, FDX1 is linked to metabolic dysfunction-associated steatotic liver disease.